Henry Jacob Conter

机构：Roche (Canada), William Osler Health System · ORCID：0000-0003-2469-3940

发表论文 91 篇 · 总被引 3208 次 · h-index 15

代表论文

Pembrolizumab Plus Docetaxel and Prednisone in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort B Study (2022 · European Urology · 被引 83)
Pembrolizumab and Enzalutamide in Patients with Abiraterone Acetate–Pretreated Metastatic Castration-Resistant Prostate Cancer: Cohort C of the Phase 1b/2 KEYNOTE-365 Study (2023 · European Urology Oncology · 被引 15)
Feasibility outcomes of a randomised, multicentre, pilot trial comparing standard 6-monthly dosing of adjuvant zoledronate with a single one-time dose in patients with early stage breast cancer (2020 · Journal of bone oncology · 被引 13)
KEYNOTE-365 cohort B: Pembrolizumab (pembro) plus docetaxel and prednisone in abiraterone (abi) or enzalutamide (enza)–pretreated patients with metastatic castration-resistant prostate cancer (mCRPC)—New data after an additional 1 year of follow-up. (2021 · Journal of Clinical Oncology · 被引 12)
MammaPrint predicts chemotherapy benefit in HR+HER2- early breast cancer: FLEX Registry real-world data (2025 · JNCI Cancer Spectrum · 被引 11)
Pembrolizumab plus Abiraterone Acetate and Prednisone in Patients with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Results from KEYNOTE-365 Cohort D (2024 · European Urology Oncology · 被引 8)